Hiberix is a Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) containing Haemophilus b capsular polysaccharide covalently bound to the Tetanus toxoid.
HIBERIX® is indicated for active immunization against invasive diseases (meningitis, septicaemia, cellulitis, arthritis, epiglottitis, etc) caused by Haemophilus influenza b bacteria. HIBERIX is approved for use in children 15 months through 4 years of age (prior to fifth birthday). HIBERIX is to be used as a booster dose in children who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primary immunization. HIBERIX is not approved for primary immunization.
HIBERIX is administered as a single dose (approximately 0.5 mL) at 15 months through 4 years of age by intramuscular injection into the anterolateral aspect of the thigh or deltoid.
HIBERIX is to be used as a booster dose in children who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primary immunization.
For latest IAP updates see revised immunization schedule.
Haemophilus influenzae type b
Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any H. influenzae type b- or tetanus toxoid-containing vaccine or any component of HIBERIX.